Clozapine treatment in adolescents with schizophrenia and autism spectrum disorder: Comparative clinical profiles and treatment outcomes from a retrospective study
- 15 February 2026
- journal article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (4) , 554-562
Abstract
Objective: Clozapine is a gold-standard antipsychotic for treatment-resistant schizophrenia, increasingly used off-label for severe autism spectrum disorder (ASD) with irritability or disruptive behaviors. This study evaluated clozapine’s efficacy and tolerability in children and adolescents with ASD or schizophrenia spectrum disorders (SSDs). Methods: A retrospective review of 26 inpatients (ASD: n = 8; SSD: n = 18) treated with clozapine included demographics, dosing, and hospitalization data. Symptom severity was assessed with the Clinical Global Impression-Severity Scale (CGI-S), Scale for the Assessment of Negative Symptoms (SANSs), Scale for the Assessment of Positive Symptoms (SAPSs), and Aberrant Behavior Checklist (ABC). Side effects were evaluated with the Ugvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale. Hematological parameters—white blood cells, neutrophils, lymphocytes, and neutrophil-to-lymphocyte ratio (NLR)—were compared pre-treatment and at 6 months. Results: Of the 26 patients, 50% had early-onset schizophrenia, 30.8% had ASD, and 19.2% had schizoaffective disorder. Clozapine was initiated at a mean age of 15.8 years, with a mean dose of 284.6 mg/day. Both SSD ( p < 0.001) and ASD ( p = 0.01) groups showed significant CGI improvement. SANS and SAPS improved in SSD ( p = 0.001, p < 0.001); ABC improved in ASD ( p = 0.012). UKU scores decreased in SSD ( p < 0.001) and trended downward in ASD ( p = 0.38). Hypersalivation (61.5%), increased appetite (53.8%), and sedation (34.6%) were common; no discontinuations occurred. Neutrophils increased ( p = 0.007), and lymphocytes decreased ( p = 0.037), with significant NLR elevation in SSD ( p = 0.006). Conclusion: Clozapine demonstrated strong efficacy and improved tolerability, reducing side effects compared to prior polypharmacy in refractory pediatric ASD and SSD.Keywords
This publication has 36 references indexed in Scilit:
- Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase dataEuropean Child & Adolescent Psychiatry, 2024
- A systematic review of clozapine‐associated inflammation and related monitoringPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- A systematic review of the role of clozapine for severe borderline personality disorderPsychopharmacology, 2023
- Prevention of suicide by clozapine in mental disorders: systematic reviewEuropean Neuropsychopharmacology, 2023
- Multi-center nationwide study on pediatric psychiatric inpatients 2000–2018: length of stay, recurrent hospitalization, functioning level, suicidality, violence and diagnostic profilesEuropean Child & Adolescent Psychiatry, 2021
- Childhood-Onset Schizophrenia and Early-onset Schizophrenia Spectrum DisordersChild and Adolescent Psychiatric Clinics of North America, 2020
- Effectiveness of clozapine for the treatment of psychosis and disruptive behaviour in a child with Atypical Autism: A case report and a brief review of the evidenceAsian Journal of Psychiatry, 2017
- How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysisEuropean Neuropsychopharmacology, 2017
- Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based studyEuropean Neuropsychopharmacology, 2015
- Sex Differences in the Timing of Identification Among Children and Adults with Autism Spectrum DisordersJournal of Autism and Developmental Disorders, 2012